DEFA14A: Beneficient Closes $1.36 Million GP Primary Capital Transaction with 8F Fund

Beneficient closed a $1.36 million primary capital transaction with 8F Fund, receiving Resettable Convertible Preferred Stock in exchange for a limited partner interest.

Summary

• Beneficient, through a subsidiary, completed a primary capital transaction with a customer involving a limited partner interest in an investment fund with a net asset value of $1,361,926.
• The customer received 136,193 shares of Series B-5 Resettable Convertible Preferred Stock in exchange.
• The Series B-5 Preferred Stock is convertible into Class A Common Stock at an initial conversion price of $0.6940 per share, subject to customary adjustments.
• A total of 468,481 shares of Series B-5 Preferred Stock are authorized.
• Each share of Series B-5 Preferred Stock is convertible into Class A Common Stock at a rate of $10.00 divided by the conversion price.
• The Series B-5 Preferred Stock will automatically convert into Class A Common Stock on the earliest of two dates: the fifth anniversary of the original issue date if certain SEC filing requirements are met, or the first date shares may be resold under Rule 144 or a resale registration statement becomes effective.
• Conversion is limited to prevent a holder from exceeding a 4.99% beneficial ownership limitation or breaching Nasdaq rules.
• The Series B-5 Preferred Stock ranks junior to existing preferred stock and all existing and future indebtedness of the company.
• In a liquidation event, holders of Series B-5 Preferred Stock will receive a pro rata share with holders of Class A Common Stock.
• Dividends will be paid on the Series B-5 Preferred Stock on an as-converted basis when, as, and if paid on the Class A Common Stock.
• Holders of Series B-5 Preferred Stock do not have voting rights, except as required by law.
• The transaction is expected to increase the collateral for the company's ExAlt loan portfolio by approximately $1.36 million.
• The company believes the transaction will result in the addition of approximately $450K (and an aggregate of approximately $10.23 million) of tangible book value attributable to the company's stockholders upon closing of the previously announced Public Stockholder Enhancement Transactions.

Sentiment

Score: 7

Explanation: The document presents a positive outlook on the company's ability to execute its business plan and drive shareholder value through strategic transactions. However, the presence of forward-looking statements and associated risks tempers the overall sentiment.

Positives

• The transaction provides Beneficient with $1.36 million in primary capital.
• The transaction is expected to increase the collateral for the company's ExAlt loan portfolio by approximately $1.36 million.
• The company believes this transaction will result in the addition of approximately $450K (and an aggregate of approximately $10.23 million) of tangible book value attributable to the company's stockholders upon closing of the previously announced Public Stockholder Enhancement Transactions.
• The GP Primary Commitment Program aims to address the potential $330 billion demand for primary commitments.

Negatives

• The Series B-5 Preferred Stock ranks junior to existing preferred stock and all existing and future indebtedness of the company, potentially diluting value for existing shareholders.
• The conversion of the Series B-5 Preferred Stock into Class A Common Stock is subject to certain limitations, including beneficial ownership and Exchange Cap restrictions, which could delay or prevent full conversion.

Risks

• The forward-looking statements are subject to risks and uncertainties that could significantly affect expected results.
• The company's ability to meet expectations regarding the timing and completion of the transaction is uncertain.
• The ultimate outcome of the transaction, including obtaining the requisite vote of securityholders, is uncertain.
• The company's ability to execute its core liquidity and primary capital business plan is subject to various risks.

Future Outlook

The company looks forward to building on this momentum in 2025 as it continues to evaluate additional opportunities that align with its strategic objectives and seeks to help satisfy the up to $330 billion of potential demand for primary commitments to meet fundraising needs.

Management Comments

• Closing this transaction underscores our commitment to executing on our core liquidity and primary capital business plan by delivering innovative capital solutions for holders and managers of alternative assets, said, Beneficient management.
• We believe this financing reflects our ability to drive shareholder value while supporting impactful, vertically integrated investment strategies that enhance the value of the collateral backing our ExAlt loan portfolio.

Industry Context

Beneficient is targeting the alternative asset investment market, providing liquidity and primary capital solutions to underserved investors, including mid-to-high net worth individuals, small-to-midsized institutions, and General Partners.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• However, the focus on providing liquidity solutions for alternative assets is a growing trend in the financial industry.
• Companies like Moonfare and ADDX are also working to democratize access to alternative investments, but their specific transaction structures and financial metrics may differ.

Stakeholder Impact

• Shareholders may benefit from the potential increase in tangible book value.
• The transaction provides capital to 8F Fund, potentially benefiting its investors.
• The transaction is expected to increase the collateral for the company's ExAlt loan portfolio, potentially benefiting its creditors.

Next Steps

• The company will file a preliminary and definitive proxy statement with the SEC to seek stockholder approval for the issuance of Class A Common Stock upon conversion of the Series B-5 Preferred Stock.
• The company will continue to evaluate additional opportunities that align with its strategic objectives.

Key Dates

Keywords

Series B-5 Preferred Stock, primary capital, convertible preferred stock, Beneficient, alternative assets, ExAlt loan portfolio, GP Primary, 8F Fund, liquidity, financing